Registry-listed formulations

veltuzumab · mesh:C493846

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • hA20-humanized anti-CD20 antibodyRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
3(38%)

Phase Distribution

Phase 2
1
13%
Phase 1/2
7
88%

Phase Distribution

0

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1/2Combined phases
7(87.5%)
Phase 2Efficacy & side effects
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
50.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/27 (87.5%)
Phase 21 (12.5%)

Trials by Status

completed450%
terminated338%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1_2

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

NCT00596804
withdrawnphase_1_2

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

NCT01101581
completedphase_1_2

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

NCT00285428
completedphase_1_2

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

NCT00546793
terminatedphase_1_2

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00596804Phase 1/2

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Completed
NCT01101581Phase 1/2

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Withdrawn
NCT00285428Phase 1/2

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Completed
NCT00546793Phase 1/2

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Completed
NCT00547066Phase 1/2

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Terminated
NCT01147393Phase 1/2

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Terminated
NCT00989586Phase 1/2

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Completed
NCT01390545Phase 2

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Terminated

All 8 trials loaded

Drug Details

Intervention Type
Varies by study
Molecule Type
Antibody
Total Trials
8

External References

ChEMBL
CHEMBL1743088

Names & Codes

Research Codes

HA20IMMU 106monoclonal antibody IMMU-106